🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Two weeks until HFSA #HFSA2024! Late Breaking Clinical Research sessions will be 🔥🔥🔥 Additional data from #ESCCongress24 late breakers FINEARTS-HF & HELIOS-B More from STEP-HFpEF, SEQUOIA-HCM, ARIES-HM3 And brand new science! Register today! hfsa.org/asm/registrati…

#ARNI in #HF with ESRD + dialysis: ⬆️LVEF ➕⬇️☠️ with no risk of hypotension ➕ hyperkalaemia. 👉MA: bit.ly/3ZszHIi Amr Abdin EJHF Editor-in-Chief Giuseppe Galati Henry Han Jan Biegus #EJHF

❤️‍🔥New in #JACCHF 📰 Obesity, Challenges, and Weight-Loss Strategies for Patients With Ventricular Assist Devices ❤️‍🔥Amazing, comprehensive guide for clinicians on management strategies for #obesity in #LVAD JACC Journals 🔗jacc.org/doi/full/10.10…

AHF Cardiologist and IC Cardiologist costume kit …Happy Halloween! 🎃

🎯New in JACC Journals #JACCHF Can SQ Lasix avoid a hospitalization for #ADHF ? 📄 AT-HOME-HF Primary Outcome Win Ratio CV Events, HF events, change in NT PRO BNP Results ❌ 1 endpoint not stat significant ✅ ⬆️ dyspnea score, QOL, FC jacc.org/doi/10.1016/j.…

New work in JACC Journals #JACCHF, secondary analysis from the STRONG-HF clinical trial on the efficacy of high-intensity GDMT uptitration stratified by baseline presence of AFib/AFlutter Marco Metra Alexandre Mebazaa 📎 jacc.org/doi/10.1016/j.…

Our team is thrilled to have implanted our first Barostim Device by Dr Keith Jones, the first in Sacramento A huge thank you to our dedicated team and the brave patients who trust us with their care. Together, we are making strides towards a Heart Success. ❤️ @CVRx_Inc

We are excited to announce that the U.S. FDA approved our orally-administered near-complete (≥90%) stabilizer of TTR for the treatment of adult patients with transthyretin cardiac amyloidosis (ATTR-CM). We are proud of the opportunity to serve patients within this community.

Make it a December to remember….. Initiate and optimize dosing of quadruple GDMT for HFrEF ⬇️🫀Symptoms ⬇️ 🚧Functional impairment ⬇️ 📈Poor health status ⬇️💥Serious adverse events ⬇️ 🏨 Hospitalizations ⬇️ ☠️ Preventable deaths Save 1.2 million lives globally in 2025

Now in #JACCHF JACC Journals 🔥 Amazing comprehensive review of Mineralocorticoid Antagonism in Heart Failure 🫀 🔗jacc.org/doi/abs/10.101…

Excited to share our State-of-the-Art review on JACC Journals answering whether #ICD still the go-to for preventing #SCD in #HFrEF in the era of #GDMT ? #JACCHF #SoMe #EPeeps #CardioTwitter #Cardiology #cardionerds Link: sciencedirect.com/science/articl… Let's dive in! 1/10 🧵🪡👇

New in #JACCHF: in ~20K pts from TREAT-AHF registry admitted with ADHF due to #HFrEF, few discharged on 4-classes of #GDMT & many had meds d/c'd at time of discharge. We can do better. #GDMTworks. #GDMT saves lives. jacc.org/doi/10.1016/j.… editorial: jacc.org/doi/10.1016/j.…

🔥 New in JACC Journals #JACCHF Revisiting the Role of ICD's in #HF with contemporary #GDMT 🔑 Points ✅ GDMT ⬇️ risk SCD ✅ Shared Decision for ICD w/pts ✅ Ongoing trials will help ID who would benefit from ICD's 🔗 jacc.org/doi/10.1016/j.…

🔥 New in JACC Journals #JACCHF Beyond Guideline-Directed Medical Therapy: Nonpharmacologic Management for Patients With #hf 🎯 Looked at Role of: Diet. Na, Obesity, Sleep D/O, Mood D/O, Substance Use, and Exercise in #HF 🔗 jacc.org/doi/10.1016/j.…

Goodmorning #EHJCVI ☕️ CMD by PET and outcomes in patients after cardiac transplantation without epicardial allograft vasculopathy ➡️ endogen/functional pattern of CMD is associated with ⬆️ rate of adverse events and death ➡️ academic.oup.com/ehjcimaging/ad… European Society of Cardiology Journals EACVI President

🔥 New in JACC Journals #JACCHF ❓ What is prognostic impact of residual congestion after a Acute HF 🏥 📰 Reviewed data from RELAX-AHF Trial 🔑 Conclusion: Residual Congestion at Day 5 was common and independently associated with worse outcomes

✅ When RCT protocol directed, a large proportion of patients with HFrEF are treated with quadruple GDMT ❌ In clinical practice, when left to clinician discretion, it is < 1 in 10 of patients eligible that are actually treated, even in settings with no cost/access barriers

🔥 New in JACC Journals #JACCHF Excellent Review on 🎯 Current landscape of Tx for ATTR-CM 1. Review of Current Tx : 2 stabilizers, one Silencer 2. What should be first choice for Tx? Switch? Add on? 3. Despite increased awareness, many remain undiagnosed

New JACC Journals #JACCHF   ⭐️Clinical profiles & occurrence of SCD by #HCM phenotype ⭐️Performance validation of current guidelines doi: 10.1016/j.jchf.2024.12.006.

💫 New in #JACCHF JACC Journals 📰 Failure to Launch: Insights From Randomized Trials on Implementation Strategies for Guideline-Directed Therapies for Heart Failure Review discuss barriers to GDMT, implementation strategies and potential solutions 🔗jacc.org/doi/full/10.10…